On July 15, 2025, BioXcel Therapeutics, Inc. announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 18/600,419. This patent, once issued, will cover the administration of a single dose of up to 120 mcg of dexmedetomidine in an oromucosal formulation for treating acute agitation associated with schizophrenia or bipolar disorder in certain patient subpopulations. This development aligns with the recommended IGALMI dosing regime and marks the 14th Orange Book listed patent for Igalmi. The patent is set to expire on January 12, 2043, subject to patent term adjustment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.